the product in the database has an inactive status
indications:
Treatment of advanced breast cancer in postmenopausal women (there is no proven efficacy in the treatment of patients with a tumor without estrogen receptors, except for those who have previously had a clinical response to tamoxifen). Supplementary treatment of early invasive breast cancer in postmenopausal women who have been found to have estrogen receptors in the tumor. Supplementary treatment of early breast cancer in postmenopausal women with a tumor that possesses sex hormone receptors that received Tamoxifen for 2-3 years as a supplementary medicine.
Composition:
1 tabl powl. contains 1 mg of anastrozole.
Action:
A strong and selective non-steroidal aromatase inhibitor involved in the conversion of androstenedione to oestrone in peripheral tissues (subsequently transformed into estradiol). It has been shown that in post-menopausal women, the use of anastrozole 1 mg daily causes suppression of oestradiol production by over 80%. Anastrozole has no progestagen, androgenic and estrogenic activity. Anastrozole administered at a dose of up to 10 mg daily does not affect the secretion of cortisol and aldosterone both without and after the stimulation of excretion by ACTH (therefore, during treatment, no corticosteroid supplementation is required). Following oral administration, anastrozole is rapidly absorbed from the gastrointestinal tract. The maximum concentration in the blood usually occurs within 2 hours of admission (fasting). The presence of food reduces the rate of absorption to a small extent, but does not affect the extent of absorption. In postmenopausal women the pharmacokinetics of anastrozole is not age dependent. The drug binds to 40% of plasma proteins. In postmenopausal women, anastrozole is extensively metabolised, less than 10% of the dose is excreted in urine unchanged within 72 hours of admission. Anastrozole is metabolized by N-dealkylation, hydroxylation and glucuronidation. Metabolites are mainly excreted in the urine. T0,5 is 40-50 h.
Contraindications:
Hypersensitivity to anastrozole or other ingredients. Pre-menopausal patients. Pregnancy and breastfeeding. Severe renal failure (creatinine clearance <20 ml / min). Moderate or severe liver failure. Simultaneous treatment with tamoxifen. During treatment with anastrozole, estrogen-containing medicines should not be given.
Precautions:
Women diagnosed with osteoporosis or at risk of osteoporosis should have bone densitometry performed at the beginning of treatment and then at regular intervals. If necessary, start treatment or prevention of osteoporosis and regularly check the effectiveness of these activities. There are no data on the concomitant use of anastrozole and LHRH analogues - these drugs should not be used at the same time, except in clinical trials. Anastrozole reduces the concentration of estrogens in the blood and may reduce the bone mineral density; there is no data on the effect of bisphosphonates used prophylactically or in the case of reduction of bone mineral density caused by the use of anastrozole. It is not indicated in children because the safety and efficacy of this medicine has not been established in this age group. Due to the lactose content, the preparation should not be used in patients with rare hereditary galactose intolerance, Lapp lactase deficiency or malabsorption of glucose-galactose.
Pregnancy and lactation:
The drug is contraindicated in pregnant women and breastfeeding.
Side effects:
Very common: hot flashes (usually mild to moderate). Common: headache (usually mild or moderate in intensity), nausea, diarrhea (usually mild to moderate in intensity), weakness of the hair, rash (usually of mild to moderate intensity), pain and / or stiffness of the joints (usually mild or moderate intensity), weakness (usually mild to moderate). Uncommon: somnolence (usually mild to moderate), vomiting (usually mild or moderate), lack of appetite (usually mild), hypercholesterolemia (usually mild or moderate), increased γ-GT and alkaline phosphatase . Very rare: erythema multiforme, Stevens-Johnson syndrome and allergic reactions (including angioneurotic edema, urticaria and anaphylactic reactions). It reduces the level of estrogen in the blood and may reduce the bone mineral density, which may increase the risk of bone fractures in some patients.
Dosage:
Orally. Adult patients, including the elderly: 1 mg once a day.In patients with early breast cancer, treatment is recommended for 5 years. No dose adjustment is required in patients with mild to moderate renal impairment and mild hepatic insufficiency.
(C)
